Anti-cancer Properties of Dietary Supplement CELNORM against Colon and Lung Cancer: An in vitro preliminary study

Abstract

Cancer is a complex disease characterized by a cascade of events that culminate in the accumulation of several genetic alterations. Because of the high incidence and mortality rate, scientists began seeking novel medications that were harmful to cancer cells but not to healthy cells. This study aimed to investigate the effect of CELNORM and its various components individually in colon and lung cancer cells. Based on the LD50 value, colon and lung cancer cells were treated with two different dosages of curcumin, pepper, carrot and cucumber extracts, individually and CELNORM (formulation with all four ingredients). The cytotoxicity of each compound has been checked through morphological analysis and cell viability assay by using the CCK8 kit and statistically analyzed. qPCR-based Gene expression study has also been done to further validate the anti-cancerous properties of the compounds. Curcumin extract decreased cancer cell growth, as evidenced by cytotoxicity and morphological analyses, but pepper, carrot, and cucumber extracts showed a less significant reduction in cancer cell growth. CELNORM, on the other hand, had the highest significant effect in suppressing cell proliferation, indicating the novel health supplement CELNORM renders more efficacy than individual components. Gene expression analysis also verifies the anti-cancerous properties of CELNORM, though some gene expressions are not in the expected line. The morphological analysis and cell viability result has shown the efficacy of the CELNORM over the individual compounds of the CELNORM and gene expression analysis of proliferative genes such as Cyclin D, CDK6, PCNA and BCL-2 further validates the anti-cancerous properties of CELNORM and all four components.

Integrated Bioinformatics Analysis and Transcriptomics Analysis Predict Jumonji and AT Rich Interacting Domain2 (JARID2) as a Therapeutic Target in Human Cancers

“…Moreover, JARID2 has been shown to regulate PRC2 function by directing its occupancy to the chromatin and its recruitment to the target genes (Li et al, 2010;Peng et al, 2009). Additionally, EZH2, another crucial gene of PRC2, has been notably overexpressed in several cancers and is a known oncogene (Gan et al, 2018;Guan et al, 2020;Mehta et al, 2023;Solairaja et al, 2023). The knockdown of EZH2 resulted in a drastic reduction of the severity in many cancers, and therefore, numerous clinical trials are being performed to identify inhibitors targeting EZH2.…”

Apoptosis and Autophagy: Therapeutic Implications in Cancer

“…Three categories of autophagy are identified: microautophagy, macroautophagy, and chaperonemediated autophagy. Microautophagy is the non-selective degradation of cytoplasmic components and subcellular organelles in lysosomes (Wang et al, 2023;Mehta et al, 2023;Kulkarni et al, 2023). Macroautophagy is differentiated from other forms of autophagy by the formation of double-membrane vesicles that engulf and degrade cytoplasmic contents and subcellular organelles by fusing with lysosomes to form autolysosomes (Odle and Cook, 2020).…”

Metal-Based Drugs in Cancer Therapy

“…However, it is only in recent decades that the true potency of metal-based drugs in cancer treatment has come to the forefront. These compounds exhibit a unique combination of chemical versatility, biological activity, and structural diversity, making them invaluable in pursuing innovative cancer treatments (Sarma, 2016;Nath et al, 2022;Mehta et al, 2023;Rami et al, 2023).…”